EA201270143A1 - ПРИМЕНЕНИЕ БЕНЗИДАМИНА ПРИ ЛЕЧЕНИИ p40-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ - Google Patents

ПРИМЕНЕНИЕ БЕНЗИДАМИНА ПРИ ЛЕЧЕНИИ p40-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ

Info

Publication number
EA201270143A1
EA201270143A1 EA201270143A EA201270143A EA201270143A1 EA 201270143 A1 EA201270143 A1 EA 201270143A1 EA 201270143 A EA201270143 A EA 201270143A EA 201270143 A EA201270143 A EA 201270143A EA 201270143 A1 EA201270143 A1 EA 201270143A1
Authority
EA
Eurasian Patent Office
Prior art keywords
benzidamine
treatment
dependent diseases
overexpression
disease
Prior art date
Application number
EA201270143A
Other languages
English (en)
Other versions
EA022862B1 (ru
Inventor
Анджело Гульельмотти
Джорджина Мангано
Джузеппе Бьонди
Original Assignee
Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А. filed Critical Ацьенде Кимике Рьюните Анджелини Франческо A.K.P.A.Ф. С.П.А.
Publication of EA201270143A1 publication Critical patent/EA201270143A1/ru
Publication of EA022862B1 publication Critical patent/EA022862B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Применение бензидамина при лечении воспалительных заболеваний, в частности болезни Крона, ревматоидного артрита, псориатического артрита и псориаза, вызванных экспрессией или сверхэкспрессией цитокиновой субъединицы р40.
EA201270143A 2009-07-08 2010-06-23 ПРИМЕНЕНИЕ БЕНЗИДАМИНА ПРИ ЛЕЧЕНИИ p40-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ EA022862B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425270 2009-07-08
PCT/EP2010/058881 WO2011003737A1 (en) 2009-07-08 2010-06-23 USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES

Publications (2)

Publication Number Publication Date
EA201270143A1 true EA201270143A1 (ru) 2012-06-29
EA022862B1 EA022862B1 (ru) 2016-03-31

Family

ID=41279454

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270143A EA022862B1 (ru) 2009-07-08 2010-06-23 ПРИМЕНЕНИЕ БЕНЗИДАМИНА ПРИ ЛЕЧЕНИИ p40-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ

Country Status (26)

Country Link
US (1) US20120302618A1 (ru)
EP (1) EP2451452B1 (ru)
JP (1) JP5753843B2 (ru)
KR (1) KR101723996B1 (ru)
CN (1) CN102470125B (ru)
AR (1) AR077451A1 (ru)
AU (1) AU2010270425B2 (ru)
BR (1) BR112012000410B8 (ru)
CA (1) CA2760176C (ru)
CY (1) CY1116914T1 (ru)
DK (1) DK2451452T3 (ru)
EA (1) EA022862B1 (ru)
ES (1) ES2554332T3 (ru)
GE (1) GEP20146156B (ru)
HK (1) HK1165280A1 (ru)
HR (1) HRP20151393T8 (ru)
HU (1) HUE028220T2 (ru)
IL (1) IL216717A (ru)
MX (1) MX2012000498A (ru)
PL (1) PL2451452T3 (ru)
PT (1) PT2451452E (ru)
SG (2) SG10201403088XA (ru)
SI (1) SI2451452T1 (ru)
SM (1) SMT201500277B (ru)
UA (1) UA105666C2 (ru)
WO (1) WO2011003737A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2976187A1 (en) * 2015-02-09 2016-08-18 Cellix Bio Private Limited Benzydamine salts and compositions thereof useful for the treatment of mucositis
US20180244792A1 (en) * 2015-09-10 2018-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
AU2017294402A1 (en) * 2016-07-08 2018-12-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Pharmaceutical composition comprising benzydamine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (ru) 1963-08-09
IT1184123B (it) 1985-01-22 1987-10-22 Acraf Impiego della benzidamina nel trattamento delle infezioni da trichomonas vaginalis e gardnerella vaginalis
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
IT1274026B (it) 1994-03-01 1997-07-14 Acraf Composizione antitosse
IT1274655B (it) 1995-02-28 1997-07-18 Smithkline Beecham Farma Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico
PL1848403T3 (pl) * 2005-01-14 2010-09-30 Camurus Ab Preparaty bioadhezyjne o działaniu miejscowym
SI1845942T1 (sl) * 2005-01-14 2014-06-30 Camurus Ab Gnrh analogne formulacije
GB0604824D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders

Also Published As

Publication number Publication date
DK2451452T3 (en) 2015-11-23
EA022862B1 (ru) 2016-03-31
SG176686A1 (en) 2012-01-30
HRP20151393T1 (hr) 2016-01-15
AU2010270425B2 (en) 2016-07-28
GEP20146156B (en) 2014-09-10
CN102470125A (zh) 2012-05-23
PL2451452T3 (pl) 2016-03-31
KR20120052201A (ko) 2012-05-23
WO2011003737A1 (en) 2011-01-13
EP2451452B1 (en) 2015-10-07
SG10201403088XA (en) 2014-10-30
CN102470125B (zh) 2015-08-19
JP5753843B2 (ja) 2015-07-22
IL216717A (en) 2017-06-29
IL216717A0 (en) 2012-02-29
PT2451452E (pt) 2016-01-14
CA2760176A1 (en) 2011-01-13
ES2554332T3 (es) 2015-12-18
CA2760176C (en) 2017-01-03
EP2451452A1 (en) 2012-05-16
HK1165280A1 (zh) 2012-11-23
CY1116914T1 (el) 2017-04-05
HUE028220T2 (en) 2016-12-28
US20120302618A1 (en) 2012-11-29
UA105666C2 (ru) 2014-06-10
SMT201500277B (it) 2016-01-08
BR112012000410A2 (pt) 2016-04-05
JP2012532173A (ja) 2012-12-13
SI2451452T1 (sl) 2015-12-31
BR112012000410B1 (pt) 2019-12-31
HRP20151393T8 (hr) 2016-07-01
MX2012000498A (es) 2012-04-30
KR101723996B1 (ko) 2017-04-06
AU2010270425A1 (en) 2011-12-22
AR077451A1 (es) 2011-08-31
BR112012000410B8 (pt) 2020-12-08

Similar Documents

Publication Publication Date Title
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
HRP20191953T8 (hr) DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40
CY1116800T1 (el) Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
TW200732347A (en) VEGF analogs and methods of use
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
PT2334677E (pt) Compostos de triazolopiridina como inibidores das quinases pim
IL206893A0 (en) Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
MX2009007406A (es) Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
UA112425C2 (uk) ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
MX2010003574A (es) Anticuerpos il-23.
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
UA105384C2 (ru) Лечение нарушений, связанных с инсулинорезистентностью
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.